Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sinovac initiates hepatitis A vaccine trials in Ukraine
The trials are being conducted by Biolik Biopharmaceutical Company, a vaccine manufacturer located in Kharkov, Ukraine to seek regulatory approval in the country. Biolik will also market and
The trials are being conducted by Biolik Biopharmaceutical Company, a vaccine manufacturer located in Kharkov, Ukraine to seek regulatory approval in the country. Biolik will also market and
Cardica and Cook have previously entered into an agreement to develop a patent foramen ovales (PFO) closure device, whereby Cardica is responsible for the design, production and manufacturing,
David Zygun, assistant professor in the departments of critical care medicine, clinical neurosciences and community health sciences, University of Calgary, Foothills Medical Centre, Calgary Health Region, will be
Under the agreement, iMedica will grant Misys a license for the iMedica PRM 2008 practice management (PM) and electronic health record (EHR) application which Misys can use to
A co-founder of Volcano, Mr Bergheim is the managing director of Fjord Ventures, a venture capital firm he founded, and has served as chairman of Volcano’s board since
Made from a medical grade thermoplastic elastomer, i-gel is said to have been designed to create a non-inflatable, anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures while
Under the agreement, initial development and integration will be a joint effort between the two companies. Once development is complete, Varian will offer customers a fully integrated 7T
Mr Murdolo joins Forest following 11 years with GlaxoSmithKline where he was vice president of investor relations, with overall responsibility for managing the North American investor relations program.
Under the agreement, Proteologics will discover and conduct early development of cancer treatments, while Teva will proceed with later stages of development, manufacturing and worldwide commercialization of the
The Phase Ia, double-blind, placebo controlled study for EDP-322 announced is a single ascending dose trial in healthy volunteers. The clinical development program for EDP-322 will include the